- Home
- ANAB vs NBBK Comparison
ANAB vs NBBK Comparison
Compare ANAB & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NBBK
- Stock Information
- Founded
- ANAB 2005
- NBBK 1892
- Country
- ANAB United States
- NBBK United States
- Employees
- ANAB N/A
- NBBK N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NBBK
- Sector
- ANAB Health Care
- NBBK
- Exchange
- ANAB Nasdaq
- NBBK Nasdaq
- Market Cap
- ANAB 621.1M
- NBBK 687.7M
- IPO Year
- ANAB 2017
- NBBK N/A
- Fundamental
- Price
- ANAB $23.41
- NBBK $18.76
- Analyst Decision
- ANAB Buy
- NBBK Buy
- Analyst Count
- ANAB 10
- NBBK 1
- Target Price
- ANAB $44.25
- NBBK $22.00
- AVG Volume (30 Days)
- ANAB 566.9K
- NBBK 471.3K
- Earning Date
- ANAB 08-04-2025
- NBBK 07-23-2025
- Dividend Yield
- ANAB N/A
- NBBK N/A
- EPS Growth
- ANAB N/A
- NBBK 421.39
- EPS
- ANAB N/A
- NBBK 1.18
- Revenue
- ANAB $111,872,000.00
- NBBK $169,131,000.00
- Revenue This Year
- ANAB N/A
- NBBK N/A
- Revenue Next Year
- ANAB $24.39
- NBBK N/A
- P/E Ratio
- ANAB N/A
- NBBK $16.05
- Revenue Growth
- ANAB 387.20
- NBBK 27.71
- 52 Week Low
- ANAB $12.21
- NBBK $14.84
- 52 Week High
- ANAB $41.31
- NBBK $21.05
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- NBBK 75.82
- Support Level
- ANAB $21.87
- NBBK $17.70
- Resistance Level
- ANAB $24.69
- NBBK $17.31
- Average True Range (ATR)
- ANAB 1.19
- NBBK 0.47
- MACD
- ANAB -0.09
- NBBK 0.27
- Stochastic Oscillator
- ANAB 61.20
- NBBK 90.91
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.